Skip to main content

Table 5 Overview of Adverse Events

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Event

Grade

Cilengitide + Gemcitabine n = 44

Gemcitabine n = 42

  

No.

Pts (%)

No.

Pts (%)

AE

All

923

100%

755

100%

 

Grade 1/2

812

27%

617

17%

 

Grade 3/4

111

73%

138

83%

SAE

All

50

55%

64

71%

  1. Adverse events with onset during the treatment phase.
  2. Abbreviations: Pts, patients; AE, adverse event; SAE, serious adverse event.